CTLA4 and B-cell non-Hodgkin lymphoma: They then demonstrated that intratumoral injections of the vaccine could overcome resistance and synergize with anti-CTLA-4 and anti-PD-L1 antibodies in four different models (Neuro2a neuroblastoma, A20 B-cell lymphoma, EMT6 breast mammary carcinoma and CT26 colon carcinoma).